drugset / Trial / NCT04557735
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study will evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of ravulizumab administered by intravenous infusion to pediatric participants, from 1 month to \< 18 years of age, with HSCT-TMA. The treatment period is 26 weeks, followed by a 26-week off-treatment follow-up period.
Timeline
- Start
- 2020-12-07
- Primary completion
- 2024-11-26
- Completion
- 2025-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ravulizumab | Monoclonal antibody | — | Intravenous |